Epidermal growth factor receptor as a biomarker for cervical cancer

Annals of Oncology

Volumn 22, Issue 10, 2011, Pages 2166-2178

  Soonthornthum, T ^a   Arias pulido, H ^a   Joste, N ^a   Lomo, L ^a   Muller, C ^a   Rutledge, T ^a   Verschraegen, C ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Biomarker; Cervical cancer; Epidermal growth factor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; MATUZUMAB; NERATINIB; TOPOTECAN; TRASTUZUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CYTOTOXICITY; DIMERIZATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TUMOR VOLUME; UPREGULATION; UTERINE CERVIX CANCER;

EID: 80053148870     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq723     Document Type: Review

References (100)

1. Quinn MA, Benedet JL, Odicino F et al. Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 (Suppl 1): S43-S103.
2. Movva S, Rodriguez L, Arias-Pulido H, Verschraegen C. Novel chemotherapy approaches for cervical cancer. Cancer 2009; 115: 3166-3180.
3. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 (Suppl 4): 2-8.
4. Chapman WB, Lorincz AT, Willett GD et al. Epidermal growth factor receptor expression and the presence of human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynecol Pathol 1992; 11: 221-226.
5. Bosch FX, Lorincz A, Munoz N et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265.
6. Zhang B, Srirangam A, Potter DA, Roman A. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 2005; 24: 2585-2588.
7. Straight SW, Hinkle PM, Jewers RJ, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993; 67: 4521-4532.
8. Tsai TC, Chen SL. The biochemical and biological functions of human papillomavirus type 16 E5 protein. Arch Virol 2003; 148: 1445-1453.
9. Akerman GS, Tolleson WH, Brown KL et al. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer Res 2001; 61: 3837-3843.
10. Sizemore N, Choo CK, Eckert RL, Rorke EA. Transcriptional regulation of the EGF receptor promoter by HPV16 and retinoic acid in human ectocervical epithelial cells. Exp Cell Res 1998; 244: 349-356.
11. Hu G, Liu W, Mendelsohn J et al. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst 1997; 89: 1271-1276.
12. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004; 109: 157-162.
13. Arias-Pulido H, Joste N, Chavez A et al. Absence of epidermal growth factor receptor mutations in cervical cancer. Int J Gynecol Cancer 2008; 18: 749-754.
14. Longatto-Filho A, Pinheiro C, Martinho O et al. Molecular characterization of 565 EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer 2009; 9: 212.
15. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 (Suppl 4): S9-S15.
16. West CM, Joseph L, Bhana S. Epidermal growth factor receptor-targeted therapy. Br J Radiol 2008; 81 Spec No 1: S36-S44.
17. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-2319.
18. Rivera F, Garcia-Castano A, Vega N et al. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther 2009; 9: 1421-1428.
19. Senderowicz AM, Johnson JR, Sridhara R et al. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park) 2007; 21: 1696-1706; discussion 1706-1699, 1712, 1715.
20. Johnson JR, Cohen M, Sridhara R et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005; 11: 6414-6421.
21. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
22. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
23. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
24. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
25. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
26. Jonker DJ, Karapetis C, Harbison C et al. High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care (BSC). J Clin Oncol 2009; 27: (Abstr 4016).
27. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-5909.
28. Eiblmaier M, Meyer LA, Watson MA et al. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med 2008; 49: 1472-1479.
29. Bellone S, Frera G, Landolfi G et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 2007; 106: 513-520.
30. Kawamoto T, Kishimoto K, Takahashi K et al. Polymorphonuclear leukocytes-mediated lysis of A431 cells induced by IgG1 mouse anti-epidermal growth factor receptor monoclonal antibodies. In Vitro Cell Dev Biol 1992; 28A: 782-786.
31. Hambek M, Solbach C, Schnuerch HG et al. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res 2001; 61: 1045-1049.
32. Meira DD, de Almeida VH, Mororo JS et al. Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. Br J Cancer 2009; 101: 782-791.
33. Chen Y, Low TY, Choong LY et al. Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells. Proteomics 2007; 7: 2384-2397.
34. Wikstrand CJ, Hale LP, Batra SK et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55: 3140-3148.
35. Ji H, Zhao X, Yuza Y et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 2006; 103: 7817-7822.
36. Sarkaria JN, Yang L, Grogan PT et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007; 6: 1167-1174.
37. Lee JC, Vivanco I, Beroukhim R et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 2006; 3: e485.
38. Kang S, Kim HS, Seo SS et al. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecol Oncol 2007; 105: 662-666.
39. Cho NH, Kim YB, Park TK et al. P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. Gynecol Oncol 2003; 91: 346-353.
40. Gaffney DK, Haslam D, Tsodikov A et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56: 922-928.
41. Hale RJ, Buckley CH, Gullick WJ et al. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 1993; 46: 149-153.
42. Gullick WJ, Downward J, Waterfield MD. Antibodies to the autophosphorylation sites of the epidermal growth factor receptor protein-tyrosine kinase as probes of structure and function. EMBO J 1985; 4: 2869-2877.
43. Kedzia W, Schmidt M, Frankowski A, Spaczynski M. Immunohistochemical assay of p53, cyclin D1, c-erbB2, EGFr and Ki-67 proteins in HPV-positive and HPV-negative cervical cancers. Folia Histochem Cytobiol 2002; 40: 37-41.
44. Kersemaekers AM, Fleuren GJ, Kenter GG et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999; 5: 577-586.
45. Adamson ED, Rees AR. Epidermal growth factor receptors. Mol Cell Biochem 1981; 34: 129-152.
46. Kim GE, Kim YB, Cho NH et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res 2004; 10: 1366-1374.
47. Kristensen GB, Holm R, Abeler VM, Trope CG. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996; 78: 433-440.
48. Noordhuis MG, Eijsink JJ, Ten Hoor KA et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res 2009; 15: 7389-7397.
49. Perez-Regadera J, Sanchez-Munoz A, De-la-Cruz J et al. Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer. Oncology 2009; 76: 133-141.
50. Pillai MR, Jayaprakash PG, Nair MK. Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J Cancer Res Clin Oncol 1998; 124: 456-461.
51. Baltazar F, Filho AL, Pinheiro C et al. Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. Int J Gynecol Pathol 2007; 26: 235-241.
52. Cohen S, Ushiro H, Stoscheck C, Chinkers M. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 1982; 257: 1523-1531.
53. Cerciello F, Riesterer O, Sherweif M et al. Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix? Gynecol Oncol 2007; 106: 394-399.
54. Chang JL, Tsao YP, Liu DW et al. The expression of type I growth factor receptors in the squamous neoplastic changes of uterine cervix. Gynecol Oncol 1999; 73: 62-71.
55. Hayashi Y, Hachisuga T, Iwasaka T et al. Expression of ras oncogene product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement. Gynecol Oncol 1991; 40: 147-151.
56. Hove MG, Dinh TV, Hannigan EV et al. Oncogene expression and microvessel count in recurrent and nonrecurrent stage Ib squamous cell carcinoma of the cervix. J Reprod Med 1999; 44: 493-496.
57. Lindstrom AK, Tot T, Stendahl U et al. Discrepancies in expression and prognostic value of tumor markers in adenocarcinoma and squamous cell carcinoma in cervical cancer. Anticancer Res 2009; 29: 2577-2578.
58. Maruo T, Yamasaki M, Ladines-Llave CA, Mochizuki M. Immunohistochemical demonstration of elevated expression of epidermal growth factor receptor in the neoplastic changes of cervical squamous epithelium. Cancer 1992; 69: 1182-1187.
59. Ngan HY, Cheung AN, Liu SS et al. Abnormal expression of pan-ras, c-myc and tp53 in squamous cell carcinoma of cervix: correlation with HPV and prognosis. Oncol Rep 2001; 8: 557-561.
60. Berger MS, Gullick WJ, Greenfield C et al. Epidermal growth factor receptors in lung tumours. J Pathol 1987; 152: 297-307.
61. Shen L, Shui Y, Wang X et al. EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy. BMC Cancer 2008; 8: 232.
62. Skomedal H, Kristensen GB, Lie AK, Holm R. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol Oncol 1999; 73: 223-228.
63. Yamashita H, Murakami N, Asari T et al. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer. Int J Radiat Oncol Biol Phys 2009; 74: 1165-1172.
64. Fuchs I, Vorsteher N, Buhler H et al. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res 2007; 27: 959-963.
65. Ngan HY, Cheung AN, Liu SS et al. Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis. Tumour Biol 2001; 22: 176-183.
66. Reiner A, Spona J, Reiner G et al. Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Am J Pathol 1986; 125: 443-449.
67. Remmele W, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 1993; 189: 862-866.
68. Robertson KW, Reeves JR, Lannigan AK et al. Radioimmunohistochemistry of epidermal growth factor receptor in breast cancer. Arch Pathol Lab Med 2002; 126: 177-181.
69. Regitnig P, Reiner A, Dinges HP et al. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 2002; 441: 328-334.
70. Bishop JW, Marcelpoil R, Schmid J. Machine scoring of Her2/neu immunohistochemical stains. Anal Quant Cytol Histol 2002; 24: 257-262.
71. Messersmith W, Oppenheimer D, Peralba J et al. Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. Cancer Biol Ther 2005; 4: 1381-1386.
72. Rahman M, Abd-El-Barr M, Mack V et al. Optical imaging of cervical pre-cancers with structured illumination: an integrated approach. Gynecol Oncol 2005; 99: S112-S115.
73. Nida DL, Rahman MS, Carlson KD et al. Fluorescent nanocrystals for use in early cervical cancer detection. Gynecol Oncol 2005; 99: S89-S94.
74. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145-182.
75. Marzano R, Corrado G, Merola R et al. Analysis of chromosomes 3, 7, X and the EGFR gene in uterine cervical cancer progression. Euro J Cancer 2004; 40: 1624-1629.
76. Kim JW, Kim YT, Kim DK et al. Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecol Oncol 1996; 60: 283-287.
77. Kim JW, Kim YT, Kim DK. Correlation between EGFR and c-erbB-2 oncoprotein status and response to neoadjuvant chemotherapy in cervical carcinoma. Yonsei Med J 1999; 40: 207-214.
78. Kim YT, Park SW, Kim JW. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol 2002; 87: 84-89.
79. Oh MJ, Choi JH, Kim IH et al. Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin Cancer Res 2000; 6: 4760-4763.
80. Kohler M, Janz I, Wintzer HO et al. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 1989; 9: 1537-1547.
81. Pfeiffer D, Kimmig R, Herrmann J et al. Epidermal-growth-factor receptor correlates negatively with cell density in cervical squamous epithelium and is down-regulated in cancers of the human uterus. Int J Cancer 1998; 79: 49-55.
82. Pfeiffer D, Stellwag B, Pfeiffer A et al. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1989; 33: 146-150.
83. Scambia G, Ferrandina G, Distefano M et al. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Lett 1998; 123: 135-139.
84. Kimmig R, Pfeiffer D, Landsmann H, Hepp H. Quantitative determination of the epidermal growth factor receptor in cervical cancer and normal cervical epithelium by 2-color flow cytometry: evidence for down-regulation in cervical cancer. Int J Cancer 1997; 74: 365-373.
85. van Dam PA, Lowe DG, Watson JV et al. Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tract. Gynecol Oncol 1991; 42: 256-264.
86. van Dam PA, Lowe DG, Watson JV, Shepherd JH. Multiparameter flow cytometric measurement of epidermal growth factor receptor and c-erbB-2 oncoprotein in cultured cells and in fresh and preserved solid tumor cells. Int J Gynecol Cancer 1995; 5: 20-28.
87. Kang S, Kim JW, Park NH et al. Epidermal growth factor 61 A/G polymorphism and uterine cervical cancer. Int J Gynecol Cancer 2007; 17: 492-496.
88. Mitsuhashi A, Tanaka N, Suzuka K et al. Detection of epidermal growth factor receptor mRNA in peripheral blood of cervical cancer patients. Gynecol Oncol 2003; 89: 480-485.
89. Gullick WJ, Marsden JJ, Whittle N et al. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res 1986; 46: 285-292.
90. Lyng H, Beigi M, Svendsrud DH et al. Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix. Int J Cancer 2004; 111: 358-366.
91. Hertlein L, Lenhard M, Kirschenhofer A et al. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet 2011; 283: 109-113.
92. Goncalves A, Fabbro M, Lhomme C et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008; 108: 42-46.
93. Candelaria M, Arias-Bonfill D, Chavez-Blanco A et al. Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha. Int J Gynecol Cancer 2009; 19: 1632-1637.
94. Monk BJ, Mas Lopez L, Zarba JJ et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010; 28: 3562-3569.
95. Taja-Chayeb L, Chavez-Blanco A, Martinez-Tlahuel J et al. Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. Cancer Cell Int 2006; 6: 22.
96. Wang HL, Lu DW. Overexpression of c-kit protein is an infrequent event in small cell carcinomas of the uterine cervix. Mod Pathol 2004; 17: 732-738.
97. Farley JH, Sill M, Walker JL et al. Phase II evaluation of cisplatin plus cetuximab in the treatment of recurrent and persistent cancers of the cervix: a limited access phase II study of the Gynecologic Oncology Group. J Clin Oncol 2009; 27: A5521.
98. Kurtz JE, Hardy-Bessard AC, Deslandres M et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol Oncol 2009; 113: 16-20.
99. Ferreira CG, Erlich F, Carmo CC et al. Erlotinib (E) combined with cisplatin (C) and radiotherapy (RT) for patients with locally advanced squamous cell cervical cancer: a phase II trial. J Clin Oncol 2008: 26 (Abstr 5511).
100. Nogueira-Rodrigues A, do Carmo CC, Viegas C et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clin Cancer Res 2008; 14: 6324-6329.